<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02583256</url>
  </required_header>
  <id_info>
    <org_study_id>V118_05E3</org_study_id>
    <secondary_id>2015-002973-39</secondary_id>
    <nct_id>NCT02583256</nct_id>
  </id_info>
  <brief_title>Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)</brief_title>
  <official_title>A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to Either the Same or Alternate Type of Vaccine, Adjuvanted or Non-adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV or QIV), Administered to Subjects Previously Vaccinated in Trial V118_05 (NCT01964989)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seqirus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seqirus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared
      to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously vaccinated in Trial
      V118_05. Subjects will receive either the Same or Alternate Type of Vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2016</start_date>
  <completion_date type="Actual">May 9, 2017</completion_date>
  <primary_completion_date type="Actual">November 15, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis</measure>
    <time_frame>Day 22</time_frame>
    <description>GMT and 95% confidence interval (CI) were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis</measure>
    <time_frame>Day 22</time_frame>
    <description>GMT and 95% CI were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)</measure>
    <time_frame>Day 22</time_frame>
    <description>GMT and 95% CI were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)</measure>
    <time_frame>Day 181</time_frame>
    <description>GMT and 95% CI were analyzed for Day 181 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)</measure>
    <time_frame>Day 1, Day 22</time_frame>
    <description>The percentage of subjects achieving seroconversion at Day 22 after vaccination is reported against homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer &lt;1:10 on Day 1) as postvaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains</measure>
    <time_frame>Day 22, Day 181</time_frame>
    <description>The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains</measure>
    <time_frame>Day 22, Day 181</time_frame>
    <description>The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination is reported against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains</measure>
    <time_frame>Day 22</time_frame>
    <description>The percentage of subjects achieving HI Titers ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 at Day 22 after vaccination is reported against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains</measure>
    <time_frame>Day 1, Day 22, Day 181</time_frame>
    <description>GMT and 95% CI were analyzed for Day 22 for the heterologous strains using ANCOVA with study specific covariates.
The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/ Victoria lineage strain, B/Malaysia/2506/2004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains</measure>
    <time_frame>Day 22/Day 1 and Day 181/Day 1</time_frame>
    <description>The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the heterologous strains using ANCOVA with study specific covariates.
The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B Victoria lineage strain, B/Malaysia/2506/2004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains</measure>
    <time_frame>Day 22, Day 181</time_frame>
    <description>The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination and the percentage of subject who experienced seroconversion is reported for homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer &lt;1:10 on Day 1) as post-vaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.
The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/Victoria lineage strain, B/Malaysia/2506/2004.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains</measure>
    <time_frame>Day 1, Day 22, Day 181</time_frame>
    <description>To further characterize immune response, MN GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains</measure>
    <time_frame>Day 22/Day 1 and Day 181/Day 1</time_frame>
    <description>The GMR is the geometric mean of the fold increase in MN titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains</measure>
    <time_frame>Day 1, Day 22, Day 181</time_frame>
    <description>To further characterize immune response, adjusted anti-NA GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains.
Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains</measure>
    <time_frame>Day 22/Day 1 and Day 181/Day 1</time_frame>
    <description>The GMR is the geometric mean of the fold increase in anti-NA titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates.
Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Percentage of Subjects With Solicited AEs</measure>
    <time_frame>Day 1 to Day 7 after vaccination</time_frame>
    <description>Safety of revaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Percentage of Subjects With Unsolicited AEs</measure>
    <time_frame>Day 1 to Day 366</time_frame>
    <description>Safety of revaccination was assessed in terms of percentage of subjects reporting unsolicited AEs during the overall study period (Day 1 to Day 366).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.</measure>
    <time_frame>Day 1 to Day 366</time_frame>
    <description>Safety of revaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCD, AESI and medically attended AE. Each subject was followed for a period of 12 months after receipt of the study vaccine.
NOCDs include AEs that represents a new diagnosis of a chronic medical condition that was not present or suspected in a subject prior to study enrollment. AESIs include potentially immune-mediated disorders which were reported by the investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature</measure>
    <time_frame>Day 1 to Day 366</time_frame>
    <description>Safety of revaccination was assessed in terms of percentage of subjects reporting diagnosis of failure to thrive or short stature up to 12 months after last vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness</measure>
    <time_frame>Day 1 to Day 366</time_frame>
    <description>Safety of revaccination was assessed in terms of percentage of subjects reporting otitis media, or pneumonia, or influenza-like illness up to 12 months after last vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains</measure>
    <time_frame>Day 22, Day 181</time_frame>
    <description>The percentage of subjects achieving MN titer ≥1:20, ≥1:40, ≥1:80 ≥1:160, ≥1:320 and ≥1:640 at Day 22 and Day 181 after vaccination is reported against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains</measure>
    <time_frame>Day 22, Day 181</time_frame>
    <description>The percentage of subjects achieving anti-NA titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 after vaccination is reported against homologous strains
Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1601</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>aQIV/aQIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with aQIV followed one year later by aQIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aQIV/QIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with aQIV followed one year later by QIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV/aQIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with QIV followed one year later by aQIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QIV/QIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects previously vaccinated with QIV followed one year later by QIV</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adjuvanted QIV (aQIV)</intervention_name>
    <description>Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
    <arm_group_label>QIV/aQIV</arm_group_label>
    <arm_group_label>aQIV/aQIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Non-adjuvanted QIV</intervention_name>
    <description>Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
    <arm_group_label>QIV/QIV</arm_group_label>
    <arm_group_label>aQIV/QIV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In order to participate in this study, all subjects must meet ALL of the inclusion criteria
        described.

          -  Subject's parent/legal guardian has voluntarily given written informed consent after
             the nature of the study has been explained according to local regulatory requirements,
             prior to study entry.

          -  Male or female subject who has completed their Visit 13 (Study Day 366 for non-naïve
             subjects) or clinic Visit 15 (Day 390 for naïve subjects) in parent trial V118_05.

          -  For naïve subjects in parent trial V118_05 to have received two doses of the same
             study vaccine (i.e. 2 doses of aQIV or 2 doses of QIV).

        Exclusion Criteria:

          -  Previous immunization with any influenza vaccine (licensed or investigational) within
             6 months prior to enrollment.

          -  Subjects with a clinical condition representing a contraindication to intramuscular
             vaccination or blood draws.

          -  Unwillingness of the parent(s)/ legal guardian(s) of the subject to refuse to
             participate in another clinical trial while enrolled in V118-05E3.

        Additional eligibility criteria may be discussed by contacting the site.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>7 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Program Director</last_name>
    <role>Study Director</role>
    <affiliation>Seqirus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site- 001</name>
      <address>
        <city>Espoo</city>
        <state>Etelä-Suomen Lääni</state>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 002</name>
      <address>
        <city>Helsinki</city>
        <state>Etelä-Suomen Lääni</state>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 003</name>
      <address>
        <city>Helsinki</city>
        <state>Etelä-Suomen Lääni</state>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 004</name>
      <address>
        <city>Järvenpää</city>
        <state>Etelä-Suomen Lääni</state>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 005</name>
      <address>
        <city>Kokkola</city>
        <state>Länsi-Suomen Lääni</state>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 007</name>
      <address>
        <city>Pori</city>
        <state>Länsi-Suomen Lääni</state>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 009</name>
      <address>
        <city>Tampere</city>
        <state>Länsi-Suomen Lääni</state>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 010</name>
      <address>
        <city>Turku</city>
        <state>Länsi-Suomen Lääni</state>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 006</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 303</name>
      <address>
        <city>Laguna</city>
        <state>Matro Manila</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 304</name>
      <address>
        <city>Muntinlupa</city>
        <state>National Capital Region</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 305</name>
      <address>
        <city>Muntinlupa</city>
        <state>National Capital Region</state>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 306</name>
      <address>
        <city>Cavite</city>
        <zip>4114</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 325</name>
      <address>
        <city>Pathum Thani</city>
        <state>Bangkok</state>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 327</name>
      <address>
        <city>Bangkok</city>
        <state>Krung Thep Maha Nakhon [Bangko</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 320</name>
      <address>
        <city>Bangkok</city>
        <state>Samut Prakan</state>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site- 323</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Philippines</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>October 16, 2015</study_first_submitted>
  <study_first_submitted_qc>October 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2015</study_first_posted>
  <results_first_submitted>February 25, 2019</results_first_submitted>
  <results_first_submitted_qc>April 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 24, 2019</results_first_posted>
  <disposition_first_submitted>September 30, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>October 16, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">October 19, 2017</disposition_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza Vaccine</keyword>
  <keyword>MF59 adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at 17 sites in total; 9 sites in Finland, 4 sites in the Philippines and 4 sites in Thailand.</recruitment_details>
      <pre_assignment_details>All enrolled subjects were included in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>aQIV/aQIV</title>
          <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
        </group>
        <group group_id="P2">
          <title>aQIV/QIV</title>
          <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
        <group group_id="P3">
          <title>QIV/aQIV</title>
          <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
        </group>
        <group group_id="P4">
          <title>QIV/QIV</title>
          <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="403"/>
                <participants group_id="P3" count="402"/>
                <participants group_id="P4" count="393"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Exposed</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="403"/>
                <participants group_id="P3" count="402"/>
                <participants group_id="P4" count="393"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="400"/>
                <participants group_id="P2" count="401"/>
                <participants group_id="P3" count="400"/>
                <participants group_id="P4" count="390"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative/Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>aQIV/aQIV</title>
          <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
        </group>
        <group group_id="B2">
          <title>aQIV/QIV</title>
          <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
        <group group_id="B3">
          <title>QIV/aQIV</title>
          <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
        </group>
        <group group_id="B4">
          <title>QIV/QIV</title>
          <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="403"/>
            <count group_id="B2" value="403"/>
            <count group_id="B3" value="402"/>
            <count group_id="B4" value="393"/>
            <count group_id="B5" value="1601"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="17.12"/>
                    <measurement group_id="B2" value="52.3" spread="17.02"/>
                    <measurement group_id="B3" value="53.4" spread="17.32"/>
                    <measurement group_id="B4" value="53.3" spread="17.30"/>
                    <measurement group_id="B5" value="53.0" spread="16.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="197"/>
                    <measurement group_id="B2" value="189"/>
                    <measurement group_id="B3" value="206"/>
                    <measurement group_id="B4" value="178"/>
                    <measurement group_id="B5" value="770"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="206"/>
                    <measurement group_id="B2" value="214"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="215"/>
                    <measurement group_id="B5" value="831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="403"/>
                    <measurement group_id="B3" value="402"/>
                    <measurement group_id="B4" value="392"/>
                    <measurement group_id="B5" value="1599"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="364"/>
                    <measurement group_id="B2" value="364"/>
                    <measurement group_id="B3" value="362"/>
                    <measurement group_id="B4" value="355"/>
                    <measurement group_id="B5" value="1445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="210"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="213"/>
                    <measurement group_id="B4" value="212"/>
                    <measurement group_id="B5" value="846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                    <measurement group_id="B2" value="153"/>
                    <measurement group_id="B3" value="150"/>
                    <measurement group_id="B4" value="143"/>
                    <measurement group_id="B5" value="600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Risk Status</title>
          <description>Subjects with underlying conditions that posed high risk of influenza complications (at risk/not at risk)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>At risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not at risk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="393"/>
                    <measurement group_id="B2" value="383"/>
                    <measurement group_id="B3" value="384"/>
                    <measurement group_id="B4" value="380"/>
                    <measurement group_id="B5" value="1540"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis</title>
        <description>GMT and 95% confidence interval (CI) were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22</time_frame>
        <population>Immunogenicity per protocol set (PPS) consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop reverse transcription polymerase chain reaction(RT-PCR) confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Noninferiority Analysis</title>
          <description>GMT and 95% confidence interval (CI) were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>Immunogenicity per protocol set (PPS) consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop reverse transcription polymerase chain reaction(RT-PCR) confirmed influenza infection between baseline and Visit 2.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="398"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1219.00" lower_limit="1137.35" upper_limit="1306.52"/>
                    <measurement group_id="O2" value="1020.89" lower_limit="953.22" upper_limit="1093.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2355.52" lower_limit="2226.19" upper_limit="2492.35"/>
                    <measurement group_id="O2" value="2529.83" lower_limit="2392.90" upper_limit="2674.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276.23" lower_limit="252.73" upper_limit="301.92"/>
                    <measurement group_id="O2" value="232.82" lower_limit="213.25" upper_limit="254.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388.35" lower_limit="355.33" upper_limit="424.44"/>
                    <measurement group_id="O2" value="328.42" lower_limit="300.76" upper_limit="358.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H1N1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H3N2.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Yamagata.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Victoria.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis</title>
        <description>GMT and 95% CI were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22</time_frame>
        <population>The immunogenicity full analysis set (FAS) consisting of all subjects who received a study vaccination and provided immunogenicity data at both Visit 1 (baseline) and at least one post-vaccination visit.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (aQIV-primed Comparison), Superiority Analysis</title>
          <description>GMT and 95% CI were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The immunogenicity full analysis set (FAS) consisting of all subjects who received a study vaccination and provided immunogenicity data at both Visit 1 (baseline) and at least one post-vaccination visit.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1218.91" lower_limit="1137.02" upper_limit="1306.70"/>
                    <measurement group_id="O2" value="1023.37" lower_limit="955.72" upper_limit="1095.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2345.71" lower_limit="2216.84" upper_limit="2482.07"/>
                    <measurement group_id="O2" value="2521.60" lower_limit="2385.43" upper_limit="2665.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="274.75" lower_limit="251.09" upper_limit="300.65"/>
                    <measurement group_id="O2" value="230.51" lower_limit="210.97" upper_limit="251.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387.35" lower_limit="354.15" upper_limit="423.66"/>
                    <measurement group_id="O2" value="326.68" lower_limit="299.10" upper_limit="356.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H1N1.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority criterion for the GMT ratio: Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should exceed 1.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H3N2.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should exceed 1.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Yamagata.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should exceed 1.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Victoria.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should exceed 1.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.1</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)</title>
        <description>GMT and 95% CI were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22</time_frame>
        <population>The immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 22 Against Homologous Strains (QIV-primed Comparison)</title>
          <description>GMT and 95% CI were analyzed for Day 22 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="397"/>
                <count group_id="O2" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1206.20" lower_limit="1123.80" upper_limit="1294.65"/>
                    <measurement group_id="O2" value="866.51" lower_limit="807.30" upper_limit="930.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2369.95" lower_limit="2236.39" upper_limit="2511.48"/>
                    <measurement group_id="O2" value="2229.48" lower_limit="2103.42" upper_limit="2363.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.54" lower_limit="202.12" upper_limit="242.82"/>
                    <measurement group_id="O2" value="156.01" lower_limit="142.32" upper_limit="171.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="330.94" lower_limit="302.38" upper_limit="362.21"/>
                    <measurement group_id="O2" value="244.03" lower_limit="222.84" upper_limit="267.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H1N1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of QIV-aQIV/QIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.28</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H3N2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of QIV-aQIV/QIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Yamagata.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of QIV-aQIV/QIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.27</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Victoria.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of QIV-aQIV/QIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.22</ci_lower_limit>
            <ci_upper_limit>1.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)</title>
        <description>GMT and 95% CI were analyzed for Day 181 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 181</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: GMT and GMT Ratio as Determined by HI Assay on Day 181 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)</title>
          <description>GMT and 95% CI were analyzed for Day 181 against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="397"/>
                <count group_id="O4" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="489.45" lower_limit="449.93" upper_limit="532.45"/>
                    <measurement group_id="O2" value="411.72" lower_limit="378.83" upper_limit="447.46"/>
                    <measurement group_id="O3" value="429.06" lower_limit="393.73" upper_limit="467.57"/>
                    <measurement group_id="O4" value="307.36" lower_limit="282.02" upper_limit="334.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1423.38" lower_limit="1310.04" upper_limit="1546.52"/>
                    <measurement group_id="O2" value="1438.40" lower_limit="1325.53" upper_limit="1560.89"/>
                    <measurement group_id="O3" value="1233.84" lower_limit="1133.08" upper_limit="1343.56"/>
                    <measurement group_id="O4" value="1222.21" lower_limit="1121.92" upper_limit="1331.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.01" lower_limit="88.67" upper_limit="106.13"/>
                    <measurement group_id="O2" value="86.43" lower_limit="79.09" upper_limit="94.45"/>
                    <measurement group_id="O3" value="73.37" lower_limit="66.88" upper_limit="80.49"/>
                    <measurement group_id="O4" value="56.57" lower_limit="51.56" upper_limit="62.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.32" lower_limit="115.17" upper_limit="142.97"/>
                    <measurement group_id="O2" value="115.26" lower_limit="103.57" upper_limit="128.26"/>
                    <measurement group_id="O3" value="104.93" lower_limit="94.02" upper_limit="117.10"/>
                    <measurement group_id="O4" value="79.76" lower_limit="71.41" upper_limit="89.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H1N1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H3N2.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Yamagata.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.01</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Victoria.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of aQIV-aQIV/aQIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H1N1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of QIV-aQIV/QIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H3N2.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of QIV-aQIV/QIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Yamagata.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of QIV-aQIV/QIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Victoria.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Lower bound of two-sided 95% CI on the ratio of QIV-aQIV/QIV-QIV HI GMT should not fall below 0.667.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>1.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)</title>
        <description>The percentage of subjects achieving seroconversion at Day 22 after vaccination is reported against homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer &lt;1:10 on Day 1) as postvaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 1, Day 22</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Seroconversion Rate (SCR) on Day 22 Against Homologous Strains (aQIV-primed and QIV-primed Comparison)</title>
          <description>The percentage of subjects achieving seroconversion at Day 22 after vaccination is reported against homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer &lt;1:10 on Day 1) as postvaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="397"/>
                <count group_id="O4" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" lower_limit="57.8" upper_limit="67.4"/>
                    <measurement group_id="O2" value="60.9" lower_limit="55.9" upper_limit="65.7"/>
                    <measurement group_id="O3" value="72.04" lower_limit="67.35" upper_limit="76.40"/>
                    <measurement group_id="O4" value="62.37" lower_limit="57.34" upper_limit="67.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.9" lower_limit="64.1" upper_limit="73.4"/>
                    <measurement group_id="O2" value="68.0" lower_limit="63.2" upper_limit="72.6"/>
                    <measurement group_id="O3" value="72.80" lower_limit="68.13" upper_limit="77.12"/>
                    <measurement group_id="O4" value="76.74" lower_limit="72.21" upper_limit="80.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.4" lower_limit="71.9" upper_limit="80.4"/>
                    <measurement group_id="O2" value="72.0" lower_limit="67.4" upper_limit="76.4"/>
                    <measurement group_id="O3" value="79.44" lower_limit="75.11" upper_limit="83.32"/>
                    <measurement group_id="O4" value="66.49" lower_limit="61.51" upper_limit="71.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4" lower_limit="73.0" upper_limit="81.4"/>
                    <measurement group_id="O2" value="74.8" lower_limit="70.2" upper_limit="79.0"/>
                    <measurement group_id="O3" value="77.92" lower_limit="73.49" upper_limit="81.92"/>
                    <measurement group_id="O4" value="69.55" lower_limit="64.66" upper_limit="74.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H1N1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower bound of two-sided 95% CI on the difference between SCR should not be below -10%.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H3N2.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower bound of two-sided 95% CI on the difference between SCR should not be below -10%.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>0.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>7.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Yamagata.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower bound of two-sided 95% CI on the difference between SCR should not be below -10%.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>4.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Victoria.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower bound of two-sided 95% CI on the difference between SCR should not be below -10%.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>2.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H1N1.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower bound of two-sided 95% CI on the difference between SCR should not be below -10%.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>9.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.11</ci_lower_limit>
            <ci_upper_limit>16.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain A/H3N2.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower bound of two-sided 95% CI on the difference between SCR should not be below -10%.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>-3.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.02</ci_lower_limit>
            <ci_upper_limit>2.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Yamagata.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower bound of two-sided 95% CI on the difference between SCR should not be below -10%.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>12.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>6.73</ci_lower_limit>
            <ci_upper_limit>19.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Comparison performed for strain B/Victoria.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The lower bound of two-sided 95% CI on the difference between SCR should not be below -10%.</non_inferiority_desc>
            <param_type>SCR difference</param_type>
            <param_value>8.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.17</ci_lower_limit>
            <ci_upper_limit>14.54</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains</title>
        <description>The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22, Day 181</time_frame>
        <population>The immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Geometric Mean Ratio (GMR) as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 for Against Homologous Strains</title>
          <description>The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="397"/>
                <count group_id="O4" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.69" lower_limit="7.17" upper_limit="8.24"/>
                    <measurement group_id="O2" value="6.44" lower_limit="6.01" upper_limit="6.90"/>
                    <measurement group_id="O3" value="7.61" lower_limit="7.09" upper_limit="8.17"/>
                    <measurement group_id="O4" value="5.47" lower_limit="5.09" upper_limit="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" lower_limit="2.86" upper_limit="3.38"/>
                    <measurement group_id="O2" value="2.61" lower_limit="2.40" upper_limit="2.84"/>
                    <measurement group_id="O3" value="2.72" lower_limit="2.50" upper_limit="2.97"/>
                    <measurement group_id="O4" value="1.95" lower_limit="1.79" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.02" lower_limit="8.53" upper_limit="9.55"/>
                    <measurement group_id="O2" value="9.69" lower_limit="9.17" upper_limit="10.25"/>
                    <measurement group_id="O3" value="9.08" lower_limit="8.57" upper_limit="9.62"/>
                    <measurement group_id="O4" value="8.54" lower_limit="8.06" upper_limit="9.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.44" lower_limit="5.01" upper_limit="5.91"/>
                    <measurement group_id="O2" value="5.50" lower_limit="5.07" upper_limit="5.97"/>
                    <measurement group_id="O3" value="4.72" lower_limit="4.33" upper_limit="5.14"/>
                    <measurement group_id="O4" value="4.67" lower_limit="4.29" upper_limit="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.81" lower_limit="7.14" upper_limit="8.54"/>
                    <measurement group_id="O2" value="6.58" lower_limit="6.03" upper_limit="7.19"/>
                    <measurement group_id="O3" value="6.26" lower_limit="5.71" upper_limit="6.86"/>
                    <measurement group_id="O4" value="4.41" lower_limit="4.02" upper_limit="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" lower_limit="2.50" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.44" lower_limit="2.23" upper_limit="2.67"/>
                    <measurement group_id="O3" value="2.07" lower_limit="1.89" upper_limit="2.27"/>
                    <measurement group_id="O4" value="1.60" lower_limit="1.46" upper_limit="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.86" lower_limit="7.19" upper_limit="8.59"/>
                    <measurement group_id="O2" value="6.64" lower_limit="6.09" upper_limit="7.26"/>
                    <measurement group_id="O3" value="6.70" lower_limit="6.12" upper_limit="7.33"/>
                    <measurement group_id="O4" value="4.94" lower_limit="4.51" upper_limit="5.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" lower_limit="2.33" upper_limit="2.89"/>
                    <measurement group_id="O2" value="2.33" lower_limit="2.09" upper_limit="2.59"/>
                    <measurement group_id="O3" value="2.12" lower_limit="1.90" upper_limit="2.36"/>
                    <measurement group_id="O4" value="1.61" lower_limit="1.44" upper_limit="1.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains</title>
        <description>The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination is reported against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22, Day 181</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Percentage of Subjects With HI Titer ≥1:40 on Day 22 and Day 181 Against Homologous Strains</title>
          <description>The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination is reported against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="397"/>
                <count group_id="O4" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O4" value="99.7" lower_limit="98.6" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O2" value="99.2" lower_limit="97.8" upper_limit="99.8"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.8" upper_limit="99.8"/>
                    <measurement group_id="O4" value="95.9" lower_limit="93.4" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="99.1" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O4" value="98.7" lower_limit="97.0" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.8" upper_limit="99.5"/>
                    <measurement group_id="O2" value="98.7" lower_limit="97.1" upper_limit="99.6"/>
                    <measurement group_id="O3" value="98.5" lower_limit="96.7" upper_limit="99.4"/>
                    <measurement group_id="O4" value="96.6" lower_limit="94.3" upper_limit="98.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.3" lower_limit="91.5" upper_limit="96.3"/>
                    <measurement group_id="O2" value="93.9" lower_limit="91.1" upper_limit="96.1"/>
                    <measurement group_id="O3" value="83.9" lower_limit="79.9" upper_limit="87.4"/>
                    <measurement group_id="O4" value="76.1" lower_limit="71.5" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.9" lower_limit="98.6" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="99.1" upper_limit="100"/>
                    <measurement group_id="O3" value="99.5" lower_limit="98.2" upper_limit="99.9"/>
                    <measurement group_id="O4" value="97.9" lower_limit="95.9" upper_limit="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="92.7" upper_limit="97.1"/>
                    <measurement group_id="O2" value="93.9" lower_limit="91.1" upper_limit="96.1"/>
                    <measurement group_id="O3" value="86.7" lower_limit="83.0" upper_limit="89.9"/>
                    <measurement group_id="O4" value="76.9" lower_limit="72.2" upper_limit="80.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains</title>
        <description>The percentage of subjects achieving HI Titers ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 at Day 22 after vaccination is reported against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoints: Percentage of Subjects With HI Titer ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 on Day 22 Against Homologous Strains</title>
          <description>The percentage of subjects achieving HI Titers ≥1:110, ≥1:151, ≥1:215, ≥1:330 and ≥1:629 at Day 22 after vaccination is reported against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="398"/>
                <count group_id="O3" value="397"/>
                <count group_id="O4" value="389"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1, HI ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.7" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.7" lower_limit="95.6" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, HI ≥1:151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.5" lower_limit="98.2" upper_limit="99.9"/>
                    <measurement group_id="O4" value="97.4" lower_limit="95.3" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, HI ≥1:215</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.2" lower_limit="97.8" upper_limit="99.8"/>
                    <measurement group_id="O3" value="97.5" lower_limit="95.4" upper_limit="98.8"/>
                    <measurement group_id="O4" value="93.8" lower_limit="90.9" upper_limit="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, HI ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.3" lower_limit="95.2" upper_limit="98.6"/>
                    <measurement group_id="O2" value="93.7" lower_limit="90.8" upper_limit="95.9"/>
                    <measurement group_id="O3" value="93.2" lower_limit="90.3" upper_limit="95.5"/>
                    <measurement group_id="O4" value="82.5" lower_limit="78.3" upper_limit="86.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/ H1N1 ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.8" lower_limit="92.1" upper_limit="96.7"/>
                    <measurement group_id="O2" value="87.6" lower_limit="84.0" upper_limit="90.7"/>
                    <measurement group_id="O3" value="87.9" lower_limit="84.3" upper_limit="91.0"/>
                    <measurement group_id="O4" value="74.2" lower_limit="69.6" upper_limit="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, HI ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="99.5" lower_limit="98.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, HI ≥1:151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.8" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="99.5" lower_limit="98.1" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, HI ≥1:215</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.5" lower_limit="98.2" upper_limit="99.9"/>
                    <measurement group_id="O2" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="99.1" upper_limit="100.0"/>
                    <measurement group_id="O4" value="97.7" lower_limit="95.6" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, HI ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.8" upper_limit="99.8"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.5" lower_limit="98.2" upper_limit="99.9"/>
                    <measurement group_id="O4" value="95.9" lower_limit="93.4" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, HI ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.0" lower_limit="97.5" upper_limit="99.7"/>
                    <measurement group_id="O2" value="99.7" lower_limit="98.6" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.2" lower_limit="97.8" upper_limit="99.8"/>
                    <measurement group_id="O4" value="95.1" lower_limit="92.4" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, HI ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8" lower_limit="87.5" upper_limit="93.4"/>
                    <measurement group_id="O2" value="88.4" lower_limit="84.8" upper_limit="91.4"/>
                    <measurement group_id="O3" value="82.7" lower_limit="78.6" upper_limit="86.3"/>
                    <measurement group_id="O4" value="68.3" lower_limit="63.4" upper_limit="73.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, HI ≥1:151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.6" lower_limit="83.9" upper_limit="90.6"/>
                    <measurement group_id="O2" value="81.6" lower_limit="77.4" upper_limit="85.3"/>
                    <measurement group_id="O3" value="75.9" lower_limit="71.4" upper_limit="80.0"/>
                    <measurement group_id="O4" value="59.9" lower_limit="54.8" upper_limit="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, HI ≥1:215</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="65.2" upper_limit="74.3"/>
                    <measurement group_id="O2" value="64.2" lower_limit="59.3" upper_limit="69.0"/>
                    <measurement group_id="O3" value="53.3" lower_limit="48.2" upper_limit="58.3"/>
                    <measurement group_id="O4" value="38.5" lower_limit="33.6" upper_limit="43.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, HI ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="39.1" upper_limit="49.0"/>
                    <measurement group_id="O2" value="34.3" lower_limit="29.6" upper_limit="39.2"/>
                    <measurement group_id="O3" value="25.1" lower_limit="20.9" upper_limit="29.7"/>
                    <measurement group_id="O4" value="14.9" lower_limit="11.5" upper_limit="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, HI ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" lower_limit="23.5" upper_limit="32.5"/>
                    <measurement group_id="O2" value="20.9" lower_limit="17.0" upper_limit="25.2"/>
                    <measurement group_id="O3" value="14.2" lower_limit="10.9" upper_limit="18.1"/>
                    <measurement group_id="O4" value="7.3" lower_limit="4.9" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, HI ≥1:110</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.0" lower_limit="90.1" upper_limit="95.3"/>
                    <measurement group_id="O2" value="89.9" lower_limit="86.5" upper_limit="92.7"/>
                    <measurement group_id="O3" value="86.0" lower_limit="82.8" upper_limit="89.8"/>
                    <measurement group_id="O4" value="76.1" lower_limit="71.5" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, HI ≥1:151</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.3" lower_limit="88.1" upper_limit="93.9"/>
                    <measurement group_id="O2" value="87.9" lower_limit="84.3" upper_limit="90.9"/>
                    <measurement group_id="O3" value="83.0" lower_limit="78.9" upper_limit="86.6"/>
                    <measurement group_id="O4" value="70.6" lower_limit="65.8" upper_limit="75.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, HI ≥1:215</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="75.3" upper_limit="83.4"/>
                    <measurement group_id="O2" value="73.4" lower_limit="69.1" upper_limit="78.0"/>
                    <measurement group_id="O3" value="67.5" lower_limit="62.6" upper_limit="72.1"/>
                    <measurement group_id="O4" value="53.0" lower_limit="47.9" upper_limit="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, HI ≥1:330</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.7" lower_limit="53.7" upper_limit="63.6"/>
                    <measurement group_id="O2" value="48.7" lower_limit="43.8" upper_limit="53.8"/>
                    <measurement group_id="O3" value="41.9" lower_limit="37.0" upper_limit="46.9"/>
                    <measurement group_id="O4" value="32.0" lower_limit="27.4" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, HI ≥1:629</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.3" lower_limit="40.3" upper_limit="50.3"/>
                    <measurement group_id="O2" value="37.6" lower_limit="32.8" upper_limit="42.6"/>
                    <measurement group_id="O3" value="34.3" lower_limit="29.6" upper_limit="39.2"/>
                    <measurement group_id="O4" value="24.1" lower_limit="19.9" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains</title>
        <description>GMT and 95% CI were analyzed for Day 22 for the heterologous strains using ANCOVA with study specific covariates.
The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/ Victoria lineage strain, B/Malaysia/2506/2004.</description>
        <time_frame>Day 1, Day 22, Day 181</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: GMT as Determined by HI Assay on Day 1, Day 22, and Day 181 Against Heterologous Strains</title>
          <description>GMT and 95% CI were analyzed for Day 22 for the heterologous strains using ANCOVA with study specific covariates.
The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/ Victoria lineage strain, B/Malaysia/2506/2004.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H3N2 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="59.4" upper_limit="160.6"/>
                    <measurement group_id="O2" value="156.6" lower_limit="96.1" upper_limit="255.1"/>
                    <measurement group_id="O3" value="40.9" lower_limit="25.3" upper_limit="66.0"/>
                    <measurement group_id="O4" value="91.6" lower_limit="55.6" upper_limit="150.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2436.1" lower_limit="2058.0" upper_limit="2883.6"/>
                    <measurement group_id="O2" value="2415.2" lower_limit="2049.9" upper_limit="2845.5"/>
                    <measurement group_id="O3" value="2225.1" lower_limit="1872.6" upper_limit="2643.8"/>
                    <measurement group_id="O4" value="2097.2" lower_limit="1769.7" upper_limit="2485.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="898.1" lower_limit="707.5" upper_limit="1139.9"/>
                    <measurement group_id="O2" value="917.6" lower_limit="728.2" upper_limit="1156.3"/>
                    <measurement group_id="O3" value="953.2" lower_limit="746.7" upper_limit="1216.6"/>
                    <measurement group_id="O4" value="791.7" lower_limit="621.5" upper_limit="1008.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.4" lower_limit="24.6" upper_limit="45.3"/>
                    <measurement group_id="O2" value="23.8" lower_limit="17.6" upper_limit="32.2"/>
                    <measurement group_id="O3" value="15.8" lower_limit="11.8" upper_limit="21.2"/>
                    <measurement group_id="O4" value="15.9" lower_limit="11.7" upper_limit="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="327.1" lower_limit="255.7" upper_limit="418.4"/>
                    <measurement group_id="O2" value="248.4" lower_limit="195.3" upper_limit="316.0"/>
                    <measurement group_id="O3" value="283.2" lower_limit="222.8" upper_limit="359.8"/>
                    <measurement group_id="O4" value="204.8" lower_limit="159.6" upper_limit="262.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.1" lower_limit="79.3" upper_limit="144.6"/>
                    <measurement group_id="O2" value="85.6" lower_limit="63.9" upper_limit="114.7"/>
                    <measurement group_id="O3" value="77.5" lower_limit="57.9" upper_limit="103.9"/>
                    <measurement group_id="O4" value="56.0" lower_limit="41.2" upper_limit="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains</title>
        <description>The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the heterologous strains using ANCOVA with study specific covariates.
The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B Victoria lineage strain, B/Malaysia/2506/2004.</description>
        <time_frame>Day 22/Day 1 and Day 181/Day 1</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: GMR as Determined by HI Assay for Day 22/Day 1 and Day 181/Day 1 Against Heterologous Strains</title>
          <description>The GMR is the geometric mean of the fold increase in HI titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the heterologous strains using ANCOVA with study specific covariates.
The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B Victoria lineage strain, B/Malaysia/2506/2004.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H3N2 (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.67" lower_limit="12.4" upper_limit="17.4"/>
                    <measurement group_id="O2" value="14.55" lower_limit="12.3" upper_limit="17.1"/>
                    <measurement group_id="O3" value="13.40" lower_limit="11.3" upper_limit="15.9"/>
                    <measurement group_id="O4" value="12.63" lower_limit="10.7" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.31" lower_limit="4.2" upper_limit="6.7"/>
                    <measurement group_id="O2" value="5.42" lower_limit="4.3" upper_limit="6.8"/>
                    <measurement group_id="O3" value="5.63" lower_limit="4.4" upper_limit="7.2"/>
                    <measurement group_id="O4" value="4.68" lower_limit="3.7" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.40" lower_limit="10.5" upper_limit="17.1"/>
                    <measurement group_id="O2" value="10.18" lower_limit="8.0" upper_limit="13.0"/>
                    <measurement group_id="O3" value="11.60" lower_limit="9.1" upper_limit="14.7"/>
                    <measurement group_id="O4" value="8.39" lower_limit="6.5" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.38" lower_limit="3.2" upper_limit="5.9"/>
                    <measurement group_id="O2" value="3.50" lower_limit="2.6" upper_limit="4.7"/>
                    <measurement group_id="O3" value="3.17" lower_limit="2.4" upper_limit="4.3"/>
                    <measurement group_id="O4" value="2.29" lower_limit="1.7" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains</title>
        <description>The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination and the percentage of subject who experienced seroconversion is reported for homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer &lt;1:10 on Day 1) as post-vaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.
The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/Victoria lineage strain, B/Malaysia/2506/2004.</description>
        <time_frame>Day 22, Day 181</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Percentage of Subjects Achieving SCR and HI Titer ≥1:40 on Day 22 and Day 181 Against Heterologous Strains</title>
          <description>The percentage of subjects achieving HI titer ≥1:40 at Day 22 and Day 181 after vaccination and the percentage of subject who experienced seroconversion is reported for homologous strains. Seroconversion was defined in subjects seronegative at baseline (i.e. HI titer &lt;1:10 on Day 1) as post-vaccination HI titer ≥1:40 and defined in subjects seropositive at baseline (i.e. HI titer ≥1:10 on Day 1) as a minimum of a 4-fold increase in post-vaccination HI titer.
The two heterologous strains selected for HI testing in this study were the H3N2 strain, A/Hong Kong/4801/2014 (X-263B), and the B/Victoria lineage strain, B/Malaysia/2506/2004.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H3N2, SCR (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.3" lower_limit="65.8" upper_limit="87.9"/>
                    <measurement group_id="O2" value="73.7" lower_limit="60.3" upper_limit="84.5"/>
                    <measurement group_id="O3" value="83.1" lower_limit="71.0" upper_limit="91.6"/>
                    <measurement group_id="O4" value="69.0" lower_limit="55.5" upper_limit="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/ H3N2, HI titer ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="94.0" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.7" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="93.9" upper_limit="100"/>
                    <measurement group_id="O4" value="100" lower_limit="93.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/ H3N2, HI titer ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.68" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="93.8" upper_limit="100"/>
                    <measurement group_id="O4" value="98.2" lower_limit="90.4" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, SCR (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="62.1" upper_limit="85.3"/>
                    <measurement group_id="O2" value="82.1" lower_limit="69.6" upper_limit="91.1"/>
                    <measurement group_id="O3" value="81.4" lower_limit="69.1" upper_limit="90.3"/>
                    <measurement group_id="O4" value="77.6" lower_limit="64.7" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, HI titer ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.3" lower_limit="91.1" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="93.6" upper_limit="100"/>
                    <measurement group_id="O3" value="96.6" lower_limit="88.3" upper_limit="99.6"/>
                    <measurement group_id="O4" value="98.3" lower_limit="90.8" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/ Victoria, HI titer ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="81.0" upper_limit="97.1"/>
                    <measurement group_id="O2" value="83.6" lower_limit="71.2" upper_limit="92.2"/>
                    <measurement group_id="O3" value="74.1" lower_limit="61.0" upper_limit="84.7"/>
                    <measurement group_id="O4" value="64.3" lower_limit="50.4" upper_limit="76.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains</title>
        <description>To further characterize immune response, MN GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 1, Day 22, Day 181</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: GMT as Determined by Microneutralization (MN) Assay on Day 1, Day 22, and Day 181 Against Homologous Strains</title>
          <description>To further characterize immune response, MN GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.36" lower_limit="173.8" upper_limit="402.1"/>
                    <measurement group_id="O2" value="198.13" lower_limit="127.8" upper_limit="307.0"/>
                    <measurement group_id="O3" value="104.28" lower_limit="67.0" upper_limit="162.3"/>
                    <measurement group_id="O4" value="140.38" lower_limit="90.0" upper_limit="219.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2253.81" lower_limit="1713.5" upper_limit="2964.5"/>
                    <measurement group_id="O2" value="2295.46" lower_limit="1729.5" upper_limit="3046.7"/>
                    <measurement group_id="O3" value="2992.29" lower_limit="2238.5" upper_limit="3999.9"/>
                    <measurement group_id="O4" value="1543.54" lower_limit="1156.5" upper_limit="20660.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727.04" lower_limit="568.6" upper_limit="929.6"/>
                    <measurement group_id="O2" value="725.35" lower_limit="560.7" upper_limit="938.4"/>
                    <measurement group_id="O3" value="686.98" lower_limit="527.2" upper_limit="895.2"/>
                    <measurement group_id="O4" value="412.34" lower_limit="317.2" upper_limit="536.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.88" lower_limit="103.6" upper_limit="249.7"/>
                    <measurement group_id="O2" value="113.74" lower_limit="71.9" upper_limit="180.0"/>
                    <measurement group_id="O3" value="133.25" lower_limit="83.8" upper_limit="211.8"/>
                    <measurement group_id="O4" value="97.47" lower_limit="61.1" upper_limit="155.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5532.06" lower_limit="4441.7" upper_limit="6890.0"/>
                    <measurement group_id="O2" value="6649.94" lower_limit="5275.3" upper_limit="8382.7"/>
                    <measurement group_id="O3" value="5019.51" lower_limit="3978.6" upper_limit="6332.8"/>
                    <measurement group_id="O4" value="4696.37" lower_limit="3699.4" upper_limit="5962.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2069.22" lower_limit="1488.8" upper_limit="2875.9"/>
                    <measurement group_id="O2" value="2127.88" lower_limit="1500.4" upper_limit="3017.8"/>
                    <measurement group_id="O3" value="2138.80" lower_limit="1505.0" upper_limit="3039.5"/>
                    <measurement group_id="O4" value="1696.57" lower_limit="1178.4" upper_limit="2442.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.82" lower_limit="22.2" upper_limit="40.1"/>
                    <measurement group_id="O2" value="37.99" lower_limit="27.9" upper_limit="51.7"/>
                    <measurement group_id="O3" value="21.57" lower_limit="15.8" upper_limit="29.5"/>
                    <measurement group_id="O4" value="21.07" lower_limit="15.4" upper_limit="28.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388.29" lower_limit="299.1" upper_limit="504.0"/>
                    <measurement group_id="O2" value="301.39" lower_limit="229.0" upper_limit="396.7"/>
                    <measurement group_id="O3" value="247.31" lower_limit="187.6" upper_limit="326.0"/>
                    <measurement group_id="O4" value="197.51" lower_limit="149.3" upper_limit="261.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.05" lower_limit="81.4" upper_limit="140.8"/>
                    <measurement group_id="O2" value="103.59" lower_limit="77.5" upper_limit="138.5"/>
                    <measurement group_id="O3" value="82.90" lower_limit="61.9" upper_limit="111.0"/>
                    <measurement group_id="O4" value="56.03" lower_limit="41.5" upper_limit="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.66" lower_limit="33.1" upper_limit="57.6"/>
                    <measurement group_id="O2" value="43.13" lower_limit="32.3" upper_limit="57.6"/>
                    <measurement group_id="O3" value="27.96" lower_limit="20.9" upper_limit="37.4"/>
                    <measurement group_id="O4" value="33.14" lower_limit="24.7" upper_limit="44.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355.63" lower_limit="271.8" upper_limit="465.4"/>
                    <measurement group_id="O2" value="346.99" lower_limit="262.6" upper_limit="458.5"/>
                    <measurement group_id="O3" value="338.49" lower_limit="255.0" upper_limit="449.4"/>
                    <measurement group_id="O4" value="193.09" lower_limit="145.5" upper_limit="256.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.31" lower_limit="95.3" upper_limit="162.1"/>
                    <measurement group_id="O2" value="106.08" lower_limit="80.2" upper_limit="140.3"/>
                    <measurement group_id="O3" value="95.87" lower_limit="72.1" upper_limit="127.5"/>
                    <measurement group_id="O4" value="60.54" lower_limit="45.4" upper_limit="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains</title>
        <description>The GMR is the geometric mean of the fold increase in MN titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22/Day 1 and Day 181/Day 1</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: GMR as Determined by MN Assay for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains</title>
          <description>The GMR is the geometric mean of the fold increase in MN titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed for the homologous strains using ANCOVA with study specific covariates.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1 (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.85" lower_limit="9.0" upper_limit="15.6"/>
                    <measurement group_id="O2" value="12.07" lower_limit="9.1" upper_limit="16.0"/>
                    <measurement group_id="O3" value="15.73" lower_limit="11.8" upper_limit="21.0"/>
                    <measurement group_id="O4" value="8.11" lower_limit="6.1" upper_limit="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1 (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" lower_limit="2.9" upper_limit="4.7"/>
                    <measurement group_id="O2" value="3.66" lower_limit="2.8" upper_limit="4.7"/>
                    <measurement group_id="O3" value="3.47" lower_limit="2.7" upper_limit="4.5"/>
                    <measurement group_id="O4" value="2.08" lower_limit="1.6" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.19" lower_limit="22.6" upper_limit="35.1"/>
                    <measurement group_id="O2" value="33.88" lower_limit="26.9" upper_limit="42.7"/>
                    <measurement group_id="O3" value="25.57" lower_limit="20.3" upper_limit="32.3"/>
                    <measurement group_id="O4" value="23.93" lower_limit="18.8" upper_limit="30.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.63" lower_limit="7.6" upper_limit="14.8"/>
                    <measurement group_id="O2" value="10.93" lower_limit="7.7" upper_limit="15.5"/>
                    <measurement group_id="O3" value="10.99" lower_limit="7.7" upper_limit="15.6"/>
                    <measurement group_id="O4" value="8.72" lower_limit="6.1" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.11" lower_limit="10.9" upper_limit="18.3"/>
                    <measurement group_id="O2" value="10.95" lower_limit="8.3" upper_limit="14.4"/>
                    <measurement group_id="O3" value="8.99" lower_limit="6.8" upper_limit="11.8"/>
                    <measurement group_id="O4" value="7.18" lower_limit="5.4" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.97" lower_limit="3.0" upper_limit="5.2"/>
                    <measurement group_id="O2" value="3.84" lower_limit="2.9" upper_limit="5.1"/>
                    <measurement group_id="O3" value="3.07" lower_limit="2.3" upper_limit="4.1"/>
                    <measurement group_id="O4" value="2.08" lower_limit="1.5" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.43" lower_limit="7.2" upper_limit="12.3"/>
                    <measurement group_id="O2" value="9.20" lower_limit="7.0" upper_limit="12.2"/>
                    <measurement group_id="O3" value="8.97" lower_limit="6.8" upper_limit="11.9"/>
                    <measurement group_id="O4" value="5.12" lower_limit="3.9" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" lower_limit="2.5" upper_limit="4.2"/>
                    <measurement group_id="O2" value="2.77" lower_limit="2.1" upper_limit="3.7"/>
                    <measurement group_id="O3" value="2.51" lower_limit="1.9" upper_limit="3.3"/>
                    <measurement group_id="O4" value="1.58" lower_limit="1.2" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains</title>
        <description>To further characterize immune response, adjusted anti-NA GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains.
Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 1, Day 22, Day 181</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Anti-neuraminidase (NA) GMTs on Day 1, Day 22, and Day 181 Against Homologous Strains</title>
          <description>To further characterize immune response, adjusted anti-NA GMT and 95% CI were analyzed for Day 1, Day 22, and Day 181 against homologous strains.
Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N1 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1174.69" lower_limit="767.8" upper_limit="1797.3"/>
                    <measurement group_id="O2" value="1209.21" lower_limit="815.7" upper_limit="1792.6"/>
                    <measurement group_id="O3" value="230.09" lower_limit="154.7" upper_limit="342.2"/>
                    <measurement group_id="O4" value="182.80" lower_limit="122.7" upper_limit="272.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3403.72" lower_limit="2821.4" upper_limit="4106.2"/>
                    <measurement group_id="O2" value="3161.01" lower_limit="2654.7" upper_limit="3763.9"/>
                    <measurement group_id="O3" value="3588.43" lower_limit="2994.0" upper_limit="4300.9"/>
                    <measurement group_id="O4" value="2410.65" lower_limit="2001.2" upper_limit="2903.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2477.65" lower_limit="1958.9" upper_limit="3133.7"/>
                    <measurement group_id="O2" value="1649.89" lower_limit="1324.9" upper_limit="2054.5"/>
                    <measurement group_id="O3" value="2018.32" lower_limit="1610.4" upper_limit="2529.5"/>
                    <measurement group_id="O4" value="870.73" lower_limit="691.0" upper_limit="1097.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2 (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.59" lower_limit="121.3" upper_limit="345.2"/>
                    <measurement group_id="O2" value="289.86" lower_limit="178.6" upper_limit="470.4"/>
                    <measurement group_id="O3" value="86.08" lower_limit="52.8" upper_limit="140.3"/>
                    <measurement group_id="O4" value="86.34" lower_limit="52.9" upper_limit="140.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="915.19" lower_limit="753.5" upper_limit="1111.6"/>
                    <measurement group_id="O2" value="1050.44" lower_limit="876.7" upper_limit="1258.7"/>
                    <measurement group_id="O3" value="1242.36" lower_limit="1031.4" upper_limit="1496.5"/>
                    <measurement group_id="O4" value="980.87" lower_limit="813.8" upper_limit="1182.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505.91" lower_limit="375.2" upper_limit="682.2"/>
                    <measurement group_id="O2" value="565.69" lower_limit="426.7" upper_limit="749.9"/>
                    <measurement group_id="O3" value="516.51" lower_limit="388.6" upper_limit="686.4"/>
                    <measurement group_id="O4" value="369.04" lower_limit="277.5" upper_limit="490.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497.11" lower_limit="344.3" upper_limit="717.7"/>
                    <measurement group_id="O2" value="548.92" lower_limit="390.7" upper_limit="771.2"/>
                    <measurement group_id="O3" value="306.48" lower_limit="217.6" upper_limit="431.7"/>
                    <measurement group_id="O4" value="237.96" lower_limit="168.7" upper_limit="335.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3175.99" lower_limit="2736.5" upper_limit="3686.0"/>
                    <measurement group_id="O2" value="3336.65" lower_limit="2906.2" upper_limit="3830.8"/>
                    <measurement group_id="O3" value="3331.87" lower_limit="2894.6" upper_limit="3835.2"/>
                    <measurement group_id="O4" value="2418.50" lower_limit="2094.6" upper_limit="2792.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1424.38" lower_limit="1108.1" upper_limit="1831.0"/>
                    <measurement group_id="O2" value="1587.86" lower_limit="1256.5" upper_limit="2006.6"/>
                    <measurement group_id="O3" value="1443.37" lower_limit="1140.1" upper_limit="1827.3"/>
                    <measurement group_id="O4" value="1030.77" lower_limit="810.3" upper_limit="1311.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290.06" lower_limit="202.3" upper_limit="415.8"/>
                    <measurement group_id="O2" value="282.17" lower_limit="201.7" upper_limit="394.8"/>
                    <measurement group_id="O3" value="148.35" lower_limit="106.0" upper_limit="207.6"/>
                    <measurement group_id="O4" value="126.07" lower_limit="90.0" upper_limit="176.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1288.67" lower_limit="1094.6" upper_limit="1517.2"/>
                    <measurement group_id="O2" value="1250.88" lower_limit="1074.3" upper_limit="1456.5"/>
                    <measurement group_id="O3" value="1275.06" lower_limit="1093.5" upper_limit="1486.7"/>
                    <measurement group_id="O4" value="883.66" lower_limit="756.1" upper_limit="1032.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727.17" lower_limit="560.2" upper_limit="943.9"/>
                    <measurement group_id="O2" value="596.62" lower_limit="467.2" upper_limit="762.0"/>
                    <measurement group_id="O3" value="511.73" lower_limit="400.7" upper_limit="653.5"/>
                    <measurement group_id="O4" value="391.23" lower_limit="305.3" upper_limit="501.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains</title>
        <description>The GMR is the geometric mean of the fold increase in anti-NA titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates.
Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22/Day 1 and Day 181/Day 1</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Anti-NA GMR for Day 22/Day 1 and Day 181/Day 1 Against Homologous Strains</title>
          <description>The GMR is the geometric mean of the fold increase in anti-NA titer from Day 1 to Day 22 or Day 181. GMR and 95% CI were analyzed against homologous strains using ANCOVA with study specific covariates.
Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N1 (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.40" lower_limit="4.5" upper_limit="6.5"/>
                    <measurement group_id="O2" value="5.02" lower_limit="4.2" upper_limit="6.0"/>
                    <measurement group_id="O3" value="5.70" lower_limit="4.8" upper_limit="6.8"/>
                    <measurement group_id="O4" value="3.83" lower_limit="3.2" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1 (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.95" lower_limit="3.1" upper_limit="5.0"/>
                    <measurement group_id="O2" value="2.63" lower_limit="2.1" upper_limit="3.3"/>
                    <measurement group_id="O3" value="3.22" lower_limit="2.6" upper_limit="4.0"/>
                    <measurement group_id="O4" value="1.39" lower_limit="1.1" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2 (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" lower_limit="3.7" upper_limit="5.5"/>
                    <measurement group_id="O2" value="5.18" lower_limit="4.3" upper_limit="6.2"/>
                    <measurement group_id="O3" value="6.13" lower_limit="5.1" upper_limit="7.4"/>
                    <measurement group_id="O4" value="4.84" lower_limit="4.0" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2 (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.45" lower_limit="1.8" upper_limit="3.3"/>
                    <measurement group_id="O2" value="2.74" lower_limit="2.1" upper_limit="3.6"/>
                    <measurement group_id="O3" value="2.50" lower_limit="1.9" upper_limit="3.3"/>
                    <measurement group_id="O4" value="1.79" lower_limit="1.3" upper_limit="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.75" lower_limit="4.9" upper_limit="6.8"/>
                    <measurement group_id="O2" value="5.59" lower_limit="4.8" upper_limit="6.5"/>
                    <measurement group_id="O3" value="5.69" lower_limit="4.9" upper_limit="6.6"/>
                    <measurement group_id="O4" value="3.95" lower_limit="3.4" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" lower_limit="2.5" upper_limit="4.3"/>
                    <measurement group_id="O2" value="2.70" lower_limit="2.1" upper_limit="3.4"/>
                    <measurement group_id="O3" value="2.32" lower_limit="1.81" upper_limit="3.0"/>
                    <measurement group_id="O4" value="1.77" lower_limit="1.4" upper_limit="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 22/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.81" lower_limit="5.9" upper_limit="7.9"/>
                    <measurement group_id="O2" value="7.15" lower_limit="6.2" upper_limit="8.2"/>
                    <measurement group_id="O3" value="7.14" lower_limit="6.2" upper_limit="8.2"/>
                    <measurement group_id="O4" value="5.18" lower_limit="4.5" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria (Day 181/Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="2.4" upper_limit="3.9"/>
                    <measurement group_id="O2" value="3.40" lower_limit="2.7" upper_limit="4.3"/>
                    <measurement group_id="O3" value="3.09" lower_limit="2.4" upper_limit="3.9"/>
                    <measurement group_id="O4" value="2.21" lower_limit="1.7" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Percentage of Subjects With Solicited AEs</title>
        <description>Safety of revaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.</description>
        <time_frame>Day 1 to Day 7 after vaccination</time_frame>
        <population>The solicited safety set consisting of all subjects who received a study vaccination with evaluable solicited AE data recorded on a diary card.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Percentage of Subjects With Solicited AEs</title>
          <description>Safety of revaccination was assessed in terms of percentage of subjects reporting solicited AEs up to 7 days after vaccination.</description>
          <population>The solicited safety set consisting of all subjects who received a study vaccination with evaluable solicited AE data recorded on a diary card.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="402"/>
                <count group_id="O4" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.76"/>
                    <measurement group_id="O2" value="50.12"/>
                    <measurement group_id="O3" value="53.48"/>
                    <measurement group_id="O4" value="40.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Local AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.67"/>
                    <measurement group_id="O2" value="37.97"/>
                    <measurement group_id="O3" value="36.82"/>
                    <measurement group_id="O4" value="29.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Solicited Systemic AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.21"/>
                    <measurement group_id="O2" value="24.81"/>
                    <measurement group_id="O3" value="30.85"/>
                    <measurement group_id="O4" value="18.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (analgesic/antipyretic use)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.54"/>
                    <measurement group_id="O2" value="10.17"/>
                    <measurement group_id="O3" value="16.92"/>
                    <measurement group_id="O4" value="10.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Percentage of Subjects With Unsolicited AEs</title>
        <description>Safety of revaccination was assessed in terms of percentage of subjects reporting unsolicited AEs during the overall study period (Day 1 to Day 366).</description>
        <time_frame>Day 1 to Day 366</time_frame>
        <population>The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited AE data (including those where it was reported/confirmed that no events had occurred).</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Percentage of Subjects With Unsolicited AEs</title>
          <description>Safety of revaccination was assessed in terms of percentage of subjects reporting unsolicited AEs during the overall study period (Day 1 to Day 366).</description>
          <population>The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited AE data (including those where it was reported/confirmed that no events had occurred).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="402"/>
                <count group_id="O4" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.09"/>
                    <measurement group_id="O2" value="55.33"/>
                    <measurement group_id="O3" value="55.97"/>
                    <measurement group_id="O4" value="52.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Unsolicited AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.20"/>
                    <measurement group_id="O2" value="3.97"/>
                    <measurement group_id="O3" value="5.72"/>
                    <measurement group_id="O4" value="3.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.</title>
        <description>Safety of revaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCD, AESI and medically attended AE. Each subject was followed for a period of 12 months after receipt of the study vaccine.
NOCDs include AEs that represents a new diagnosis of a chronic medical condition that was not present or suspected in a subject prior to study enrollment. AESIs include potentially immune-mediated disorders which were reported by the investigators.</description>
        <time_frame>Day 1 to Day 366</time_frame>
        <population>The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited adverse event (AE) data (including those where it was reported/confirmed that no events had occurred).</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Percentage of Subjects With Serious Adverse Events (SAE), AEs Leading to Withdrawal, New Onset of Chronic Disease (NOCD), AE of Special Interest (AESI), and Medically Attended AE.</title>
          <description>Safety of revaccination was assessed in terms of percentage of subjects reporting SAEs, AEs leading to withdrawal, NOCD, AESI and medically attended AE. Each subject was followed for a period of 12 months after receipt of the study vaccine.
NOCDs include AEs that represents a new diagnosis of a chronic medical condition that was not present or suspected in a subject prior to study enrollment. AESIs include potentially immune-mediated disorders which were reported by the investigators.</description>
          <population>The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited adverse event (AE) data (including those where it was reported/confirmed that no events had occurred).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="402"/>
                <count group_id="O4" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48"/>
                    <measurement group_id="O2" value="2.73"/>
                    <measurement group_id="O3" value="1.74"/>
                    <measurement group_id="O4" value="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to withdrawal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NOCD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medically attended AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.61"/>
                    <measurement group_id="O2" value="54.34"/>
                    <measurement group_id="O3" value="53.98"/>
                    <measurement group_id="O4" value="48.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature</title>
        <description>Safety of revaccination was assessed in terms of percentage of subjects reporting diagnosis of failure to thrive or short stature up to 12 months after last vaccination.</description>
        <time_frame>Day 1 to Day 366</time_frame>
        <population>The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited AE data (including those where it was reported/confirmed that no events had occurred).</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Percentage of Subjects With Diagnosis of Failure to Thrive or Short Stature</title>
          <description>Safety of revaccination was assessed in terms of percentage of subjects reporting diagnosis of failure to thrive or short stature up to 12 months after last vaccination.</description>
          <population>The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited AE data (including those where it was reported/confirmed that no events had occurred).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="402"/>
                <count group_id="O4" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25"/>
                    <measurement group_id="O2" value="0.74"/>
                    <measurement group_id="O3" value="0.25"/>
                    <measurement group_id="O4" value="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness</title>
        <description>Safety of revaccination was assessed in terms of percentage of subjects reporting otitis media, or pneumonia, or influenza-like illness up to 12 months after last vaccination.</description>
        <time_frame>Day 1 to Day 366</time_frame>
        <population>The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited AE data (including those where it was reported/confirmed that no events had occurred).</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Endpoint: Percentage of Subjects With Otitis Media, or Pneumonia, or Influenza-like Illness</title>
          <description>Safety of revaccination was assessed in terms of percentage of subjects reporting otitis media, or pneumonia, or influenza-like illness up to 12 months after last vaccination.</description>
          <population>The unsolicited safety set consisting of all subjects who received a study vaccination with documented safety assessments for unsolicited AE data (including those where it was reported/confirmed that no events had occurred).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="403"/>
                <count group_id="O3" value="402"/>
                <count group_id="O4" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>otitis media, any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.23"/>
                    <measurement group_id="O2" value="3.47"/>
                    <measurement group_id="O3" value="3.73"/>
                    <measurement group_id="O4" value="2.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pneumonia, any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49"/>
                    <measurement group_id="O2" value="1.49"/>
                    <measurement group_id="O3" value="0.75"/>
                    <measurement group_id="O4" value="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>influenza-like illness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.94"/>
                    <measurement group_id="O2" value="10.17"/>
                    <measurement group_id="O3" value="9.20"/>
                    <measurement group_id="O4" value="7.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains</title>
        <description>The percentage of subjects achieving MN titer ≥1:20, ≥1:40, ≥1:80 ≥1:160, ≥1:320 and ≥1:640 at Day 22 and Day 181 after vaccination is reported against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22, Day 181</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data (MN titer ≥1:20, ≥1:40, ≥1:80, &gt;four-fold rise), and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Percentage of Subjects With MN Titer ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Day 22 and Day 181 Against Homologous Strains</title>
          <description>The percentage of subjects achieving MN titer ≥1:20, ≥1:40, ≥1:80 ≥1:160, ≥1:320 and ≥1:640 at Day 22 and Day 181 after vaccination is reported against homologous strains.
Strains tested: A/H1N1 California/07/2009; A/H3N2 Switzerland/9715293/2013; B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data (MN titer ≥1:20, ≥1:40, ≥1:80, &gt;four-fold rise), and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/ H1N1, ≥1:20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/ H1N1, ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:80 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:160 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="94.92" lower_limit="85.85" upper_limit="98.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:320 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.61" lower_limit="88.29" upper_limit="99.59"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="94.92" lower_limit="85.85" upper_limit="98.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:640 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.61" lower_limit="88.29" upper_limit="99.59"/>
                    <measurement group_id="O2" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                    <measurement group_id="O3" value="91.67" lower_limit="81.61" upper_limit="97.24"/>
                    <measurement group_id="O4" value="81.36" lower_limit="69.09" upper_limit="90.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:20 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="96.55" lower_limit="88.09" upper_limit="99.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:80 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="93.10" lower_limit="83.27" upper_limit="98.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:160 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.67" lower_limit="88.47" upper_limit="99.59"/>
                    <measurement group_id="O2" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                    <measurement group_id="O3" value="94.83" lower_limit="85.62" upper_limit="98.92"/>
                    <measurement group_id="O4" value="81.03" lower_limit="68.59" upper_limit="90.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:320 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.67" lower_limit="81.61" upper_limit="97.24"/>
                    <measurement group_id="O2" value="91.38" lower_limit="81.02" upper_limit="97.14"/>
                    <measurement group_id="O3" value="84.48" lower_limit="72.58" upper_limit="92.65"/>
                    <measurement group_id="O4" value="63.79" lower_limit="50.12" upper_limit="76.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H1N1, ≥1:640 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.00" lower_limit="67.67" upper_limit="89.22"/>
                    <measurement group_id="O2" value="63.79" lower_limit="50.12" upper_limit="76.01"/>
                    <measurement group_id="O3" value="55.17" lower_limit="41.54" upper_limit="68.26"/>
                    <measurement group_id="O4" value="48.28" lower_limit="34.95" upper_limit="61.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:80 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:160 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:320 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:640 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:20 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.21" lower_limit="90.45" upper_limit="99.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="96.43" lower_limit="87.69" upper_limit="99.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:80 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="91.07" lower_limit="80.38" upper_limit="97.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:160 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.67" lower_limit="88.47" upper_limit="99.59"/>
                    <measurement group_id="O2" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                    <measurement group_id="O3" value="96.55" lower_limit="88.09" upper_limit="99.58"/>
                    <measurement group_id="O4" value="89.29" lower_limit="78.12" upper_limit="95.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:320 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.67" lower_limit="81.61" upper_limit="97.24"/>
                    <measurement group_id="O2" value="94.83" lower_limit="85.62" upper_limit="98.92"/>
                    <measurement group_id="O3" value="93.10" lower_limit="83.27" upper_limit="98.09"/>
                    <measurement group_id="O4" value="85.71" lower_limit="73.78" upper_limit="93.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2, ≥1:640 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.67" lower_limit="75.41" upper_limit="94.06"/>
                    <measurement group_id="O2" value="86.21" lower_limit="74.62" upper_limit="93.85"/>
                    <measurement group_id="O3" value="84.48" lower_limit="72.58" upper_limit="92.65"/>
                    <measurement group_id="O4" value="83.93" lower_limit="71.67" upper_limit="92.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="96.67" lower_limit="88.47" upper_limit="99.59"/>
                    <measurement group_id="O4" value="96.55" lower_limit="88.09" upper_limit="99.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                    <measurement group_id="O2" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                    <measurement group_id="O3" value="96.67" lower_limit="88.47" upper_limit="99.59"/>
                    <measurement group_id="O4" value="93.10" lower_limit="83.27" upper_limit="98.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:80 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.00" lower_limit="86.08" upper_limit="98.96"/>
                    <measurement group_id="O2" value="96.61" lower_limit="88.29" upper_limit="99.59"/>
                    <measurement group_id="O3" value="95.00" lower_limit="86.08" upper_limit="98.96"/>
                    <measurement group_id="O4" value="89.66" lower_limit="78.83" upper_limit="96.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:160 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.67" lower_limit="81.61" upper_limit="97.24"/>
                    <measurement group_id="O2" value="86.44" lower_limit="75.02" upper_limit="93.96"/>
                    <measurement group_id="O3" value="78.33" lower_limit="65.80" upper_limit="87.93"/>
                    <measurement group_id="O4" value="70.69" lower_limit="57.27" upper_limit="81.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:320 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.00" lower_limit="62.14" upper_limit="85.28"/>
                    <measurement group_id="O2" value="72.88" lower_limit="59.73" upper_limit="83.64"/>
                    <measurement group_id="O3" value="65.00" lower_limit="51.60" upper_limit="76.87"/>
                    <measurement group_id="O4" value="50.00" lower_limit="36.58" upper_limit="63.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:640 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.33" lower_limit="44.88" upper_limit="70.93"/>
                    <measurement group_id="O2" value="47.46" lower_limit="34.30" upper_limit="60.88"/>
                    <measurement group_id="O3" value="31.67" lower_limit="20.26" upper_limit="44.96"/>
                    <measurement group_id="O4" value="24.14" lower_limit="13.87" upper_limit="37.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:20 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                    <measurement group_id="O2" value="96.55" lower_limit="88.09" upper_limit="99.58"/>
                    <measurement group_id="O3" value="93.10" lower_limit="83.27" upper_limit="98.09"/>
                    <measurement group_id="O4" value="80.36" lower_limit="67.57" upper_limit="89.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.33" lower_limit="83.80" upper_limit="98.15"/>
                    <measurement group_id="O2" value="93.10" lower_limit="83.27" upper_limit="98.09"/>
                    <measurement group_id="O3" value="79.31" lower_limit="66.65" upper_limit="88.83"/>
                    <measurement group_id="O4" value="71.43" lower_limit="57.79" upper_limit="82.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:80 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.67" lower_limit="58.56" upper_limit="82.55"/>
                    <measurement group_id="O2" value="72.41" lower_limit="59.10" upper_limit="83.34"/>
                    <measurement group_id="O3" value="56.90" lower_limit="42.23" upper_limit="69.84"/>
                    <measurement group_id="O4" value="46.43" lower_limit="32.99" upper_limit="60.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:160 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.00" lower_limit="32.12" upper_limit="58.39"/>
                    <measurement group_id="O2" value="48.28" lower_limit="34.95" upper_limit="61.78"/>
                    <measurement group_id="O3" value="32.76" lower_limit="21.01" upper_limit="46.34"/>
                    <measurement group_id="O4" value="17.86" lower_limit="8.91" upper_limit="30.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:320 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.00" lower_limit="14.72" upper_limit="37.86"/>
                    <measurement group_id="O2" value="24.14" lower_limit="13.87" upper_limit="37.17"/>
                    <measurement group_id="O3" value="15.52" lower_limit="7.35" upper_limit="27.42"/>
                    <measurement group_id="O4" value="7.14" lower_limit="1.98" upper_limit="17.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:640 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="0.41" upper_limit="11.53"/>
                    <measurement group_id="O2" value="8.62" lower_limit="2.86" upper_limit="18.98"/>
                    <measurement group_id="O3" value="5.17" lower_limit="1.08" upper_limit="14.38"/>
                    <measurement group_id="O4" value="3.57" lower_limit="0.44" upper_limit="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.92" lower_limit="85.85" upper_limit="98.94"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O3" value="96.67" lower_limit="88.47" upper_limit="99.59"/>
                    <measurement group_id="O4" value="93.22" lower_limit="83.54" upper_limit="98.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:80 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.53" lower_limit="81.32" upper_limit="97.19"/>
                    <measurement group_id="O2" value="96.61" lower_limit="88.29" upper_limit="99.59"/>
                    <measurement group_id="O3" value="90.00" lower_limit="79.49" upper_limit="96.24"/>
                    <measurement group_id="O4" value="84.75" lower_limit="73.01" upper_limit="92.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:160 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.44" lower_limit="75.02" upper_limit="93.96"/>
                    <measurement group_id="O2" value="86.44" lower_limit="75.02" upper_limit="93.96"/>
                    <measurement group_id="O3" value="81.67" lower_limit="69.56" upper_limit="90.48"/>
                    <measurement group_id="O4" value="69.49" lower_limit="56.13" upper_limit="80.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:320 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.58" lower_limit="61.56" upper_limit="85.02"/>
                    <measurement group_id="O2" value="67.80" lower_limit="54.36" upper_limit="79.38"/>
                    <measurement group_id="O3" value="58.33" lower_limit="44.88" upper_limit="70.93"/>
                    <measurement group_id="O4" value="35.59" lower_limit="23.55" upper_limit="49.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:640 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.15" lower_limit="35.89" upper_limit="62.50"/>
                    <measurement group_id="O2" value="42.37" lower_limit="29.61" upper_limit="55.93"/>
                    <measurement group_id="O3" value="33.33" lower_limit="21.69" upper_limit="46.69"/>
                    <measurement group_id="O4" value="22.03" lower_limit="12.29" upper_limit="34.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:20 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O3" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                    <measurement group_id="O4" value="96.43" lower_limit="87.69" upper_limit="99.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.67" lower_limit="75.41" upper_limit="94.06"/>
                    <measurement group_id="O2" value="87.93" lower_limit="76.70" upper_limit="95.01"/>
                    <measurement group_id="O3" value="74.14" lower_limit="60.96" upper_limit="84.74"/>
                    <measurement group_id="O4" value="60.71" lower_limit="46.75" upper_limit="73.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:80 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.33" lower_limit="65.80" upper_limit="87.93"/>
                    <measurement group_id="O2" value="63.79" lower_limit="50.12" upper_limit="76.01"/>
                    <measurement group_id="O3" value="44.83" lower_limit="31.74" upper_limit="58.46"/>
                    <measurement group_id="O4" value="41.07" lower_limit="28.10" upper_limit="55.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:160 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.33" lower_limit="44.88" upper_limit="70.93"/>
                    <measurement group_id="O2" value="43.10" lower_limit="30.16" upper_limit="56.77"/>
                    <measurement group_id="O3" value="27.59" lower_limit="16.66" upper_limit="40.90"/>
                    <measurement group_id="O4" value="23.21" lower_limit="12.98" upper_limit="36.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:320 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.67" lower_limit="20.26" upper_limit="44.96"/>
                    <measurement group_id="O2" value="20.69" lower_limit="11.17" upper_limit="33.35"/>
                    <measurement group_id="O3" value="18.97" lower_limit="9.87" upper_limit="31.41"/>
                    <measurement group_id="O4" value="8.93" lower_limit="2.96" upper_limit="19.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:640 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.33" lower_limit="2.76" upper_limit="18.39"/>
                    <measurement group_id="O2" value="15.52" lower_limit="7.35" upper_limit="27.42"/>
                    <measurement group_id="O3" value="12.07" lower_limit="4.99" upper_limit="23.30"/>
                    <measurement group_id="O4" value="5.36" lower_limit="1.12" upper_limit="14.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains</title>
        <description>The percentage of subjects achieving anti-NA titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 after vaccination is reported against homologous strains
Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
        <time_frame>Day 22, Day 181</time_frame>
        <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
        <group_list>
          <group group_id="O1">
            <title>aQIV/aQIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O2">
            <title>aQIV/QIV</title>
            <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
          <group group_id="O3">
            <title>QIV/aQIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
          </group>
          <group group_id="O4">
            <title>QIV/QIV</title>
            <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity Endpoint: Percentage of Subjects Achieving Anti-NA Titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 Against Homologous Strains</title>
          <description>The percentage of subjects achieving anti-NA titers ≥1:20, ≥1:40, ≥1:80, ≥1:160, ≥1:320 and ≥1:640 on Days 22 and 181 after vaccination is reported against homologous strains
Strains tested: N1 (PR8 H6N1 California/07/2009), N2 (PR8 H6N2 Switzerl/9715293/2013); B/Victoria Brisbane/60/2008; B/Yamagata Phuket/3073/2013.</description>
          <population>The Immunogenicity PPS consisting of all subjects who received a study vaccination and provided immunogenicity data, and who correctly received the study vaccine, had no major protocol deviations, and did not develop RT-PCR-confirmed influenza infection between baseline and Visit 2.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="59"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>N1, ≥1:20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:80 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:160 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="93.33" lower_limit="83.80" upper_limit="98.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:320 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="88.33" lower_limit="77.43" upper_limit="95.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1,≥1:640 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                    <measurement group_id="O4" value="85.00" lower_limit="73.43" upper_limit="92.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:20 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="93.33" lower_limit="83.80" upper_limit="98.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="91.67" lower_limit="81.61" upper_limit="97.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:80 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="86.67" lower_limit="75.41" upper_limit="94.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:160 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="96.55" lower_limit="88.09" upper_limit="99.58"/>
                    <measurement group_id="O4" value="81.67" lower_limit="69.56" upper_limit="90.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:320 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="96.72" lower_limit="88.65" upper_limit="99.60"/>
                    <measurement group_id="O3" value="93.10" lower_limit="83.27" upper_limit="98.09"/>
                    <measurement group_id="O4" value="70.00" lower_limit="56.79" upper_limit="81.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N1, ≥1:640 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="93.44" lower_limit="84.05" upper_limit="98.18"/>
                    <measurement group_id="O3" value="72.41" lower_limit="59.10" upper_limit="83.34"/>
                    <measurement group_id="O4" value="51.67" lower_limit="38.39" upper_limit="64.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:80 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.21" lower_limit="90.45" upper_limit="99.95"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                    <measurement group_id="O4" value="96.67" lower_limit="88.47" upper_limit="99.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:160 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.21" lower_limit="90.45" upper_limit="99.95"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="98.31" lower_limit="90.91" upper_limit="99.96"/>
                    <measurement group_id="O4" value="90.00" lower_limit="79.49" upper_limit="96.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:320 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.64" lower_limit="85.13" upper_limit="98.88"/>
                    <measurement group_id="O2" value="96.77" lower_limit="88.83" upper_limit="99.61"/>
                    <measurement group_id="O3" value="94.92" lower_limit="85.85" upper_limit="98.94"/>
                    <measurement group_id="O4" value="85.00" lower_limit="73.43" upper_limit="92.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:640 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.71" lower_limit="73.78" upper_limit="93.62"/>
                    <measurement group_id="O2" value="88.71" lower_limit="78.11" upper_limit="95.34"/>
                    <measurement group_id="O3" value="79.66" lower_limit="67.17" upper_limit="89.02"/>
                    <measurement group_id="O4" value="68.33" lower_limit="55.04" upper_limit="79.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:20 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="90.00" lower_limit="79.49" upper_limit="96.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.18" lower_limit="90.28" upper_limit="99.95"/>
                    <measurement group_id="O2" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                    <measurement group_id="O3" value="89.66" lower_limit="78.83" upper_limit="96.11"/>
                    <measurement group_id="O4" value="88.33" lower_limit="77.43" upper_limit="95.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:80 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.55" lower_limit="84.88" upper_limit="98.86"/>
                    <measurement group_id="O2" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                    <measurement group_id="O3" value="86.21" lower_limit="74.62" upper_limit="93.85"/>
                    <measurement group_id="O4" value="80.00" lower_limit="67.67" upper_limit="89.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:160 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.45" lower_limit="73.34" upper_limit="93.50"/>
                    <measurement group_id="O2" value="95.00" lower_limit="86.08" upper_limit="98.96"/>
                    <measurement group_id="O3" value="81.03" lower_limit="68.59" upper_limit="90.13"/>
                    <measurement group_id="O4" value="70.00" lower_limit="56.79" upper_limit="81.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:320 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.00" lower_limit="67.03" upper_limit="89.57"/>
                    <measurement group_id="O2" value="85.00" lower_limit="73.43" upper_limit="92.90"/>
                    <measurement group_id="O3" value="67.24" lower_limit="53.66" upper_limit="78.99"/>
                    <measurement group_id="O4" value="61.67" lower_limit="48.21" upper_limit="73.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>N2, ≥1:640 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.91" lower_limit="57.10" upper_limit="82.37"/>
                    <measurement group_id="O2" value="81.67" lower_limit="69.56" upper_limit="90.48"/>
                    <measurement group_id="O3" value="55.17" lower_limit="41.54" upper_limit="68.26"/>
                    <measurement group_id="O4" value="50.00" lower_limit="36.81" upper_limit="63.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.04" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:80 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.21" lower_limit="90.45" upper_limit="99.95"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:160 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.21" lower_limit="90.45" upper_limit="99.95"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:320 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.21" lower_limit="90.45" upper_limit="99.95"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="96.61" lower_limit="88.29" upper_limit="99.59"/>
                    <measurement group_id="O4" value="88.33" lower_limit="77.43" upper_limit="95.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:640 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.07" lower_limit="80.38" upper_limit="97.04"/>
                    <measurement group_id="O2" value="91.80" lower_limit="81.90" upper_limit="97.28"/>
                    <measurement group_id="O3" value="89.83" lower_limit="79.17" upper_limit="96.18"/>
                    <measurement group_id="O4" value="66.67" lower_limit="53.31" upper_limit="78.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:20 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                    <measurement group_id="O3" value="98.28" lower_limit="90.76" upper_limit="99.96"/>
                    <measurement group_id="O4" value="96.67" lower_limit="88.47" upper_limit="99.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:80 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                    <measurement group_id="O3" value="96.55" lower_limit="88.09" upper_limit="99.58"/>
                    <measurement group_id="O4" value="90.00" lower_limit="79.49" upper_limit="96.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:160 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.18" lower_limit="90.28" upper_limit="99.95"/>
                    <measurement group_id="O2" value="96.67" lower_limit="88.47" upper_limit="99.59"/>
                    <measurement group_id="O3" value="91.38" lower_limit="81.02" upper_limit="97.14"/>
                    <measurement group_id="O4" value="81.67" lower_limit="69.56" upper_limit="90.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:320 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.73" lower_limit="82.41" upper_limit="97.98"/>
                    <measurement group_id="O2" value="86.67" lower_limit="75.41" upper_limit="94.06"/>
                    <measurement group_id="O3" value="84.48" lower_limit="72.58" upper_limit="92.65"/>
                    <measurement group_id="O4" value="65.00" lower_limit="51.60" upper_limit="76.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata, ≥1:640 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.73" lower_limit="59.04" upper_limit="83.86"/>
                    <measurement group_id="O2" value="61.67" lower_limit="48.21" upper_limit="73.93"/>
                    <measurement group_id="O3" value="51.72" lower_limit="38.22" upper_limit="65.05"/>
                    <measurement group_id="O4" value="40.00" lower_limit="27.56" upper_limit="53.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:20 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:40 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:80 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:160 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:320 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="98.33" lower_limit="91.06" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:640 (Day 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.62" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.22" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.94" upper_limit="100.00"/>
                    <measurement group_id="O4" value="91.67" lower_limit="81.61" upper_limit="97.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:20 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:40 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:80 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="100.00" lower_limit="93.84" upper_limit="100.00"/>
                    <measurement group_id="O4" value="100.00" lower_limit="94.04" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:160 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.00" lower_limit="93.51" upper_limit="100.00"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="96.55" lower_limit="88.09" upper_limit="99.58"/>
                    <measurement group_id="O4" value="96.67" lower_limit="88.47" upper_limit="99.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:320 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.55" lower_limit="84.88" upper_limit="98.86"/>
                    <measurement group_id="O2" value="100.00" lower_limit="94.13" upper_limit="100.00"/>
                    <measurement group_id="O3" value="95.55" lower_limit="88.09" upper_limit="99.58"/>
                    <measurement group_id="O4" value="83.33" lower_limit="71.48" upper_limit="91.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria, ≥1:640 (Day 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.09" lower_limit="77.75" upper_limit="95.89"/>
                    <measurement group_id="O2" value="95.08" lower_limit="86.29" upper_limit="98.97"/>
                    <measurement group_id="O3" value="81.03" lower_limit="68.59" upper_limit="90.13"/>
                    <measurement group_id="O4" value="70.00" lower_limit="56.79" upper_limit="81.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Day 1 - Day 366</time_frame>
      <desc>The overall safety set included all subjects who were in the solicited safety set and/or in the unsolicited safety set.
Assessment of revaccination safety included:
SAEs collected between Day 1 to Day 366 Non-serious AEs included solicited AEs collected between Day 1 to Day 7 after last vaccination, and unsolicited AEs collected between Day 1 to Day 366 after last vaccination</desc>
      <group_list>
        <group group_id="E1">
          <title>aQIV-aQIV</title>
          <description>Subjects previously vaccinated with aQIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
        </group>
        <group group_id="E2">
          <title>aQIV-QIV</title>
          <description>Subjects previously vaccinated with aQIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
        <group group_id="E3">
          <title>QIV-aQIV</title>
          <description>Subjects previously vaccinated with QIV followed one year later by aQIV
Adjuvanted QIV (aQIV): Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)</description>
        </group>
        <group group_id="E4">
          <title>QIV-QIV</title>
          <description>Subjects previously vaccinated with QIV followed one year later by QIV
Non-adjuvanted QIV: Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Spina Bifida Occulta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aphthous Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebic Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Appendiceal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>External Ear Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal Bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Jaw Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Wound Secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="289" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="274" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="229" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Injection Site Erythema</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="39" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Injection Site Induration</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="163" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="137" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="134" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="100" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="99" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="73" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Eating Disorder</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="403"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="403"/>
                <counts group_id="E3" subjects_affected="50" subjects_at_risk="402"/>
                <counts group_id="E4" subjects_affected="36" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Seqirus Clinical Trial Disclosure Manager</name_or_title>
      <organization>Seqirus</organization>
      <phone>Phone: 1-855-358-8966</phone>
      <email>Seqirus.ClinicalTrials@Seqirus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

